Breaking News Instant updates and real-time market news.

ALKS

Alkermes

$59.29

4.6 (8.41%)

, BMY

Bristol-Myers

$65.35

1.48 (2.32%)

05:15
02/15/18
02/15
05:15
02/15/18
05:15

Alkermes catalysts are the major focus this year, says Citi

Citi analyst Liav Abraham says that while Alkermes' (ALKS) fiscal 2018 revenue outlook came in below expectations, catalysts are the "major force this year." The analyst expects data from two of the company's pivotal programs and clarity around the regulatory pathway for ALKS 5461. Further, the strategic value of ALKS 4230 "can also not be discounted," following the collaboration between Bristol-Myers (BMY) and Nektar Therapeutics (NKTR), Abraham tells investors in a post-earnings research note. ALKS 4230, an IL-2 inhibitor, gives Alkermes optionality as it is not an "obvious" fit into the company's psychiatry-oriented portfolio, the analyst contends. She keeps a Neutral rating on Alkermes with a $62 price target.

ALKS

Alkermes

$59.29

4.6 (8.41%)

BMY

Bristol-Myers

$65.35

1.48 (2.32%)

NKTR

Nektar

$84.00

8.34 (11.02%)

  • 15

    Feb

  • 26

    Feb

  • 05

    Mar

  • 08

    Mar

  • 04

    Apr

  • 03

    May

ALKS Alkermes
$59.29

4.6 (8.41%)

11/27/17
JEFF
11/27/17
NO CHANGE
Target $66
JEFF
Buy
Alkermes made prudent move selling ALKS 8700 rights, says Jefferies
Jefferies analyst Biren Amin thinks Alkermes (ALKS) made a prudent move by selling the rights of ALKS 8700 to Biogen (BIIB). The multiple sclerosis drug did not fit into the company's portfolio, Amin tells investors in an intraday research note. He believes Alkermes can now focus on programs such as ALKS-4230, an IL-2 for oncology. The analyst has a Buy rating on the shares with a $66 price target.
11/28/17
FBCO
11/28/17
NO CHANGE
Target $66
FBCO
Outperform
Alkermes agreement with Biogen should help monetize ALKS 8700, says Credit Suisse
Credit Suisse analyst Vamil Divan views Alkermes (ALKS) ALKS 8700 agreement with Biogen (BIIB) as a positive financial move for an underappreciated pipeline asset. The analyst notes that ALKS 8700 has not been given much credit by investors to date due to limited clinical data and patent uncertainty. Divan reiterates an Outperform rating and $66 price target on Alkermes shares.
11/28/17
BERN
11/28/17
NO CHANGE
Target $318
BERN
Outperform
Biogen price target raised to $318 from $310 at Bernstein
Bernstein analyst Aaron Gal raised his price target for Biogen (BIIB) to $318 from $310 after the company announced a licensing agreement with Alkermes (ALKS) to develop and commercialize ALKS 8700, a modified fumarate with a potentially differentiated GI tolerability profile. The analyst views this important improvement in Biogen's position in MS given the risk of generic Tecfidera. Further, Gal thinks the Street may be underappreciating the value of the asset. He reiterates an Outperform rating on Biogen's shares.
12/14/17
JEFF
12/14/17
NO CHANGE
Target $66
JEFF
Buy
Jefferies received positive feedback on Vivitrol at psychiatry conference
Jefferies analyst Biren Amin says he received positive feedback on Alkermes' Vivitrol at the American Academy of Addiction Psychiatry conference. Key opinion leaders have a consensus view on Vivitrol of its comparable efficacy and safety versus Suboxone, Amin tells investors in a research note. Psychiatrists view the recently approved Sublocade as a meaningful alternative to reduce abusive use of oral Suboxone, but don't believe it as a major threat to Vivitrol as physician acceptance of Vivitrol largely depends on its unique antagonist mechanism, the analyst adds. He believes Alkermes is in a strategic position for "significant growth" of Vivitrol longer term, supported by physician advocacy, patient awareness and Trump administration's pledges to fight the opioid epidemic. Amin has a Buy rating on Alkermes with a $66 price target.
BMY Bristol-Myers
$65.35

1.48 (2.32%)

02/06/18
LEER
02/06/18
NO CHANGE
Target $76
LEER
Outperform
Bristol-Myers price target raised to $76 from $71 at Leerink
Leerink analyst Seamus Fernandez raised his price target for Bristol-Myers to $76 from $71 and increased Opdivo and Yervoy estimates following positive CM-227 PFS Topline. The analyst reiterates an Outperform rating on the shares.
02/14/18
MZHO
02/14/18
NO CHANGE
Target $89
MZHO
Buy
Nektar deal with Bristol-Myers could eventually lead to takeover, says Mizuho
After Nektar (NKTR) announced a new immune-oncology collaboration agreement with Bristol-Myers Squibb (BMY), Mizuho analyst Difei Yang said she believes the deal values Nektar at approximately $9B-$10B and may lead to an eventual takeout. She maintains her Buy rating and $89 price target on Nektar shares.
02/14/18
JEFF
02/14/18
NO CHANGE
Target $88
JEFF
Buy
Nektar takeover not off table with Bristol deal, says Jefferies
Jefferies analyst David Steinberg finds it important that Nektar Therapeutics (NKTR) retains ownership of NKTR-214 following its collaboration with Bristol-Myers (BMY) and that it can continue to collaborate with other companies. Further, the potential to be acquired is not off the table, Steinberg tells investors in a research note. The analyst keeps a Buy rating on Nektar with an $88 price target.
02/15/18
MSCO
02/15/18
UPGRADE
MSCO
Overweight
Bristol-Myers upgraded to Overweight from Equal Weight at Morgan Stanley
NKTR Nektar
$84.00

8.34 (11.02%)

01/22/18
MZHO
01/22/18
NO CHANGE
Target $89
MZHO
Buy
Nektar price target raised to $89 from $45 at Mizuho
Mizuho analyst Difei Yang raised her price target for Nektar Therapeutics to $89 citing the "impressive" safety and efficacy data observed so far in clinical trials for NKTR-214. The drugmaker closed Friday up $1.43 to $71.59. There is a "good chance" the upcoming data readouts at the American Society of Clinical Oncology in June will be positive, which could provide "strong upside for the shares," Yang tells investors in a research note. The analyst believes NKTR-214 has been impressive across all cancer types and is "ahead of the competition." She believes the drug has the potential to work across many indications and points out the asset is wholly-owned by Nektar. From a potential acquirer's perspective, a wholly-owned asset is more attractive, Yang contends. She reiterates a Buy rating on Nektar.
02/05/18
JEFF
02/05/18
NO CHANGE
Target $88
JEFF
Buy
Bristol-Myers makes sense as potential Nektar acquirer, says Jefferies
Jefferies analyst David Steinberg believes Bloomberg's report that Nektar Therapeutics (NKTR) is exploring strategic options is not surprising. For many years Nektar's most important assets were out licensed, but that is no longer the case, Steinberg tells investors in a research note. The company's current partner Bristol-Myers Squibb (BMY) would make sense to be on the short list of potential acquirer, the analyst adds. Steinberg keeps a Buy rating on Nektar with an $88 price target.

TODAY'S FREE FLY STORIES

GIS

General Mills

$47.24

-0.365 (-0.77%)

20:25
03/19/19
03/19
20:25
03/19/19
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Mar

TRN

Trinity Industries

$22.46

-0.25 (-1.10%)

20:20
03/19/19
03/19
20:20
03/19/19
20:20
Hot Stocks
Trinity Industries names Leldon Echols chairman of the board »

Trinity Industries…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Mar

TIGR

UP Fintech

$0.00

(0.00%)

20:06
03/19/19
03/19
20:06
03/19/19
20:06
Syndicate
UP Fintech 13M share IPO priced at $8.00 »

The deal priced above the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Mar

SND

Smart Sand

$4.27

-0.4 (-8.57%)

20:01
03/19/19
03/19
20:01
03/19/19
20:01
Initiation
Smart Sand initiated at B. Riley FBR »

Smart Sand initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LYFT

Lyft

$0.00

(0.00%)

20:00
03/19/19
03/19
20:00
03/19/19
20:00
Initiation
Lyft initiated at DA Davidson »

Lyft initiated with a Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Mar

  • 20

    Mar

  • 21

    Mar

  • 21

    Mar

  • 22

    Mar

  • 25

    Mar

  • 26

    Mar

  • 27

    Mar

  • 28

    Mar

  • 29

    Mar

DERM

Dermira

$14.13

1.52 (12.05%)

19:40
03/19/19
03/19
19:40
03/19/19
19:40
Syndicate
Dermira 9.8M share Secondary priced at $13.25 per share »

Citi, Cowen, Cantor…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Mar

NVRO

Nevro

$44.76

0.37 (0.83%)

19:38
03/19/19
03/19
19:38
03/19/19
19:38
Upgrade
Nevro rating change at BMO Capital »

Nevro upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Mar

  • 21

    Mar

TORC

ResTORbio

$7.16

-1.81 (-20.18%)

19:34
03/19/19
03/19
19:34
03/19/19
19:34
Syndicate
ResTORbio 7.2M share Secondary priced at $6.95 »

BofA/Merrill, SVB Leerink…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Mar

NVRO

Nevro

$44.76

0.37 (0.83%)

19:33
03/19/19
03/19
19:33
03/19/19
19:33
Upgrade
Nevro rating change at BMO Capital »

Nevro upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Mar

  • 21

    Mar

PFE

Pfizer

$42.32

0.51 (1.22%)

, MKGAY

Merck KGaA

$0.00

(0.00%)

19:17
03/19/19
03/19
19:17
03/19/19
19:17
Hot Stocks
Pfizer, Merck KGaA discontinue Phase III JAVELIN Ovarian PARP study »

Merck KGaA (MKGAY) and…

PFE

Pfizer

$42.32

0.51 (1.22%)

MKGAY

Merck KGaA

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Mar

  • 30

    Apr

  • 18

    May

GOOG

Alphabet

$1,199.71

16.05 (1.36%)

, GOOGL

Alphabet Class A

$1,203.13

15.04 (1.27%)

19:11
03/19/19
03/19
19:11
03/19/19
19:11
Hot Stocks
Google outlines changes to Android mobile options, ad formats in Europe »

Google said in a blog…

GOOG

Alphabet

$1,199.71

16.05 (1.36%)

GOOGL

Alphabet Class A

$1,203.13

15.04 (1.27%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Mar

  • 04

    Apr

  • 29

    Apr

  • 29

    Apr

  • 27

    Oct

GOOG

Alphabet

$1,199.71

16.05 (1.36%)

, GOOGL

Alphabet Class A

$1,203.13

15.04 (1.27%)

19:08
03/19/19
03/19
19:08
03/19/19
19:08
Periodicals
Google offers Android, product ad concessions for Europe, WSJ says »

Google intends to ask all…

GOOG

Alphabet

$1,199.71

16.05 (1.36%)

GOOGL

Alphabet Class A

$1,203.13

15.04 (1.27%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Mar

  • 04

    Apr

  • 29

    Apr

  • 29

    Apr

  • 27

    Oct

SMAR

Smartsheet

$43.51

-0.16 (-0.37%)

, SCS

Steelcase

$17.49

-0.115 (-0.65%)

19:06
03/19/19
03/19
19:06
03/19/19
19:06
Hot Stocks
Fly Intel: After Hours Movers »

UP AFTER EARNINGS: …

SMAR

Smartsheet

$43.51

-0.16 (-0.37%)

SCS

Steelcase

$17.49

-0.115 (-0.65%)

AUPH

Aurinia Pharmaceuticals

$6.40

0.13 (2.07%)

NVRO

Nevro

$44.76

0.37 (0.83%)

SAGE

Sage Therapeutics

$156.08

-0.89 (-0.57%)

TME

Tencent Music

$18.65

-0.48 (-2.51%)

WPRT

Westport

$1.50

(0.00%)

AIR

AAR Corp.

$35.10

(0.00%)

FDX

FedEx

$181.50

-0.92 (-0.50%)

FNV

Franco-Nevada

$75.64

0.035 (0.05%)

PRNB

Principia Biopharma

$36.88

0.48 (1.32%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Mar

  • 19

    Mar

  • 19

    Mar

  • 19

    Mar

  • 19

    Mar

  • 19

    Mar

  • 19

    Mar

  • 20

    Mar

  • 20

    Mar

  • 20

    Mar

  • 21

    Mar

  • 01

    Apr

  • 02

    Apr

  • 05

    Apr

  • 14

    May

  • 28

    May

  • 24

    Jun

  • 26

    Jun

LGIH

LGI Homes

$54.89

-2.27 (-3.97%)

19:02
03/19/19
03/19
19:02
03/19/19
19:02
Hot Stocks
LGI Homes announces new community in Las Vegas »

LGI Homes, Inc. announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SAGE

Sage Therapeutics

$156.08

-0.89 (-0.57%)

19:01
03/19/19
03/19
19:01
03/19/19
19:01
Hot Stocks
Sage says Zulresso approval represents 'game-changing approach' to PPD »

Sage Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Mar

QTRX

Quanterix

$24.59

-0.01 (-0.04%)

18:55
03/19/19
03/19
18:55
03/19/19
18:55
Syndicate
Breaking Syndicate news story on Quanterix »

Quanterix files $200M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AIHS

Senmiao Technology

$4.71

-0.275 (-5.52%)

18:55
03/19/19
03/19
18:55
03/19/19
18:55
Syndicate
Breaking Syndicate news story on Senmiao Technology »

Senmiao Technology files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INVH

Invitation Homes

$23.31

-0.23 (-0.98%)

18:54
03/19/19
03/19
18:54
03/19/19
18:54
Syndicate
Breaking Syndicate news story on Invitation Homes »

Invitation Homes files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Mar

  • 20

    Mar

PULM

Pulmatrix

$1.70

-0.09 (-5.03%)

18:53
03/19/19
03/19
18:53
03/19/19
18:53
Syndicate
Breaking Syndicate news story on Pulmatrix »

Pulmatrix files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Mar

SIEN

Sientra

$8.81

-0.4 (-4.34%)

18:51
03/19/19
03/19
18:51
03/19/19
18:51
Recommendations
Sientra analyst commentary at Wells Fargo »

Sientra implied costs to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INVH

Invitation Homes

$23.31

-0.23 (-0.98%)

18:50
03/19/19
03/19
18:50
03/19/19
18:50
Syndicate
Breaking Syndicate news story on Invitation Homes »

Invitation Homes files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Mar

  • 20

    Mar

FDX

FedEx

$181.50

-0.92 (-0.50%)

18:45
03/19/19
03/19
18:45
03/19/19
18:45
Hot Stocks
FedEx CEO: Domestic business is pretty good »

In an interview on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Mar

  • 01

    Apr

  • 02

    Apr

LYFT

Lyft

$0.00

(0.00%)

18:41
03/19/19
03/19
18:41
03/19/19
18:41
Periodicals
Lyft IPO oversubscribed so far, Reuters reports »

Lyft's IPO is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Mar

  • 20

    Mar

  • 21

    Mar

  • 21

    Mar

  • 22

    Mar

  • 25

    Mar

  • 26

    Mar

  • 27

    Mar

  • 28

    Mar

  • 29

    Mar

NSTG

NanoString

$24.27

-3.03 (-11.10%)

18:37
03/19/19
03/19
18:37
03/19/19
18:37
Syndicate
NanoString 4.5M share Secondary priced at $23.00 »

JPMorgan, UBS and Cowen…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Mar

GLD

SPDR Gold Shares

$123.39

0.35 (0.28%)

18:37
03/19/19
03/19
18:37
03/19/19
18:37
Hot Stocks
Breaking Hot Stocks news story on SPDR Gold Shares »

SPDR Gold Shares holdings…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.